NCT00822354

Tadalafil for the Treatment of Raynaud's

Tadalafil for the Treatment of Secondary Raynaud's Phenomenon

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Northwestern University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The investigators propose that tadalafil will increase digital blood flow and improve the symptoms and signs of secondary Raynaud's phenomenon.

Detailed description

The primary goal of our study is to decrease the frequency, duration and severity of vasospastic attacks in patients with secondary Raynaud's. The secondary goal is to document increased blood flow and lessened capillary dysfunction in these patients. Both of these goals are to be achieved using a course of treatment with Tadalafil.We anticipate a decrease in the frequency, duration and severity of Raynaud's attacks. Improved digital blood flow and digital blood pressures, and a decrease in digital capillary dysfunction.

Conditions

• Raynaud

Interventions

Type	Name	Description
DRUG	Tadalafil	Subjects will be randomized to receive either tadalafil for the first month followed by placebo or placebo for the first month and followed by tadalafil

Timeline

• Start date: 2008-09-01
• Primary completion: 2010-02-01
• Completion: 2010-04-01
• First posted: 2009-01-14
• Last updated: 2014-12-04
• Results posted: 2014-12-04

Locations

1 site across 1 country: United States